Mineralys Therapeutics, Inc. (MLYS) Key Metrics
MLYS valuation today
Trailing 12 months · as of October 17, 2026- Market cap
- $1.79B
- Enterprise value
- $1.72B
- P/E (TTM)
- —
- Forward P/E
- —
- PEG ratio
- —
- Price / sales
- —
- Price / book
- 4.3 10-yr median 3.1
- EV / EBITDA
- —
- Dividend yield
- —
- Beta
- 0.69
MLYS key metrics, 2020–2025
Fiscal year ended December 31, 2025 · U.S. dollarsMLYS valuation Price multiples at each fiscal year-end price.
MLYS returns How much profit the business earns on the capital it uses.
MLYS per-share figures Results divided by the shares outstanding at year-end.
MLYS financial health Debt, liquidity and how easily interest is covered.
MLYS efficiency & capital use Working capital cycle and where the cash goes.
MLYS valuation history
MLYS returns on capital
Net income (ROE, ROA) or after-tax operating income (ROIC) divided by the average of the opening and closing balance.
MLYS debt vs cash
Debt includes short- and long-term borrowings and, where reported, lease liabilities.
MLYS cash returned to shareholders
MLYS price vs earnings per share
MLYS key metrics
2020–2025| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | |
|---|---|---|---|---|---|---|
| Valuation | ||||||
| Market capitalization | $2.46B | $597.5M | $311.2M | — | — | — |
| Enterprise value | $1.80B | $399.3M | $74.7M | — | — | — |
| Price / book | 3.8 | 3.1 | 1.3 | — | — | — |
| Earnings yield | −6.3% | −29.8% | −23.1% | — | — | — |
| Free cash flow yield | −5.8% | −27.8% | −26.1% | — | — | — |
| Shareholder yield (dividends + buybacks) | 0.0% | 0.0% | 0.0% | — | — | — |
| Share price at fiscal year-end | $36.29 | $12.31 | $8.60 | — | — | — |
| Per share | ||||||
| Revenue per share | $0.00 | $0.00 | $0.00 | — | — | — |
| Earnings per share | −$2.29 | −$3.66 | −$1.99 | — | — | — |
| Operating cash flow per share | −$2.10 | −$3.43 | −$2.24 | — | — | — |
| Free cash flow per share | −$2.11 | −$3.43 | −$2.24 | — | — | — |
| Cash per share | $9.71 | $4.08 | $6.54 | — | — | — |
| Book value per share | $9.56 | $3.94 | $6.66 | — | — | — |
| Tangible book value per share | $9.56 | $3.94 | $6.66 | — | — | — |
| Capex per share | $0.00 | $0.00 | $0.00 | — | — | — |
| Shares outstanding | 67.7M | 48.5M | 36.2M | — | — | — |
| Change in shares outstanding | +39.4% | +34.1% | — | — | — | — |
| Returns & profitability | ||||||
| Return on equity (ROE) | −36.9% | −82.2% | −76.1% | — | — | — |
| Return on assets (ROA) | −35.6% | −77.7% | −39.3% | −47.5% | −307.8% | −230.6% |
| Return on tangible assets | −23.4% | −86.4% | −28.6% | −26.0% | −174.5% | −230.6% |
| Financial health | ||||||
| Total debt | — | — | — | — | — | $4.5M |
| Cash & short-term investments | $656.6M | $198.2M | $236.6M | $110.1M | $10.6M | $1.4M |
| Net debt | −$656.6M | −$198.2M | −$236.6M | −$110.1M | −$10.6M | $3.1M |
| Debt / assets | — | — | — | — | — | 3.03 |
| Current ratio | 43.76 | 14.02 | 23.76 | 13.98 | 2.20 | 0.29 |
| Quick ratio | 43.76 | 14.02 | 23.76 | 13.98 | 2.20 | 0.29 |
| Interest coverage | — | — | — | -18.8 | -693.5 | -25.6 |
| Working capital | $646.3M | $190.7M | $238.6M | $104.7M | $6.1M | −$3.6M |
| Invested capital | −$9.9M | −$6.9M | $4.6M | −$162.4M | −$33.5M | −$506,000 |
| Tangible asset value | $646.7M | $191.3M | $241.2M | −$52.3M | −$22.9M | −$3.6M |
| Net current asset value | $646.3M | $190.7M | $238.6M | −$53.9M | −$22.9M | −$3.6M |
| Graham net-net per share | $9.48 | $3.78 | $6.25 | — | — | — |
| Capital allocation | ||||||
| Dividends paid | — | — | — | — | — | $3.8M |
| Share buybacks (net) | $0 | $0 | $0 | $1.6M | — | $20,000 |
| Capex / depreciation | 0.25 | 2.23 | 0.00 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||||
| Days payables outstanding | 7,720.7 | 4,583.7 | — | — | — | — |
| Payables turnover | 0.05 | 0.08 | — | — | — | — |
| Asset turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Average payables | $1.2M | $540,000 | $1.3M | $1.3M | $646,000 | $529,000 |
| Intangibles / total assets | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
Computed from MLYS's annual financial statements (latest annual report filed March 12, 2026) and the closing share price on each fiscal year-end, adjusted for stock splits. Figures in U.S. dollars; data from EODHD. Averages use the opening and closing balance of each year.
MLYS valuation and financial ratios
Mineralys Therapeutics earned a return on equity of −36.9% in fiscal 2025.
See the MLYS income statement, the MLYS chart for price history, or the MLYS stock overview for the latest quote and news.
MLYS key metrics FAQ
What is Mineralys Therapeutics's return on equity?
Mineralys Therapeutics's return on equity (ROE) was −36.9% in fiscal 2025: net income of -$154.7 million on average shareholders' equity of $419.0 million.
What is Mineralys Therapeutics's free cash flow yield?
Mineralys Therapeutics generated -$142.4 million of free cash flow in fiscal 2025, a free cash flow yield of −5.8% on its market value at year-end ($2.5 billion).
What is Mineralys Therapeutics's current ratio?
Mineralys Therapeutics's current ratio was 43.76 at the end of fiscal 2025: current assets were 43.76 times current liabilities.